Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | ALPI | P09923 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | XIAP | P98170 | 1/20 | 0.85 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPA3 | P15088 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL1637917 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL4862934 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL1011892 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL1537448 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL3496164 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL2679075 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL9650016 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL1675272 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL21816915 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL27579186 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113521299-B | Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118201943-A | Anti-inflammatory compound and application thereof | 映恩生物制药（苏州）有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118176020-A | Anti-DLL 3 antibody, antibody-drug conjugate thereof and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-118119408-A | Anti-CD 37 antibody-drug conjugates | 第一三共株式会社 | 2024-05-31 | — | — | CN | claimed |
| CN-118103359-A | Preparation method of eribulin derivative | 江苏恒瑞医药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118043080-A | Antibody coupling medicine based on microtubule inhibitor | 昆山新蕴达生物科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| WO-2024092067-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-02 | — | — | WO | claimed |
| CN-117881431-A | Antibody-conjugated drug conjugated by cleavable linker | 昆山新蕴达生物科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117813119-A | Protein-antiviral compound conjugates | 里珍纳龙药品有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117752813-A | anti-CD 33 antibodies and anti-CD 33 antibody-drug conjugates and uses thereof | 成都百利多特生物药业有限责任公司 | 2024-03-26 | — | — | CN | claimed |
| US-20140315785-A1 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2014-10-23 | — | — | US | claimed |
| US-20120142615-A1 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS | HUMAN SERVICE (US) | 2012-06-07 | — | — | US | claimed |
| US-20080038199-A1 | Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED (US) | 2008-02-14 | — | — | US | claimed |
| EP-1750711-A2 | TREATMENT OF NEUROGENERATIVE AND INFLAMMATORY CONDITIONS WITH MORPHINAN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050272093-A1 | Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof | MACKINNON RODERICK | 2005-12-08 | — | — | US | claimed |
| WO-2005112931-A2 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-12-01 | — | — | WO | claimed |
| US-6641997-B1 | Tetrameric, two-transmembrane-domain-type bound to a solid support; substituting amino acids to permit binding to agitoxin; use in treating cardiac arrhythmia, diabetes, seizures, asthma and hypertension | THE ROCKEFELLER UNIVERSITY | 2003-11-04 | — | — | US | claimed |
| EP-1062508-A1 | ASSAYS FOR SCREENING COMPOUNDS WHICH INTERACT WITH CATION CHANNEL PROTEINS, MUTANT PROKARYOTIC CATION CHANNEL PROTEINS, AND USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999047923-A9 | ASSAYS FOR SCREENING COMPOUNDS WHICH INTERACT WITH CATION CHANNEL PROTEINS, MUTANT PROKARYOTIC CATION CHANNEL PROTEINS, AND USES THEREOF | UNIV ROCKEFELLER (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999047923-A2 | ASSAYS FOR SCREENING COMPOUNDS WHICH INTERACT WITH CATION CHANNEL PROTEINS, MUTANT PROKARYOTIC CATION CHANNEL PROTEINS, AND USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1999-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038199-A1 | Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions | VGF, NLN, BDNF | ADORA3 2358/4885SLC7A5 2995/4885PTGS1 1037/4885 |
| US-20120142615-A1 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS | VGF, NLN, BDNF | ADORA3 2358/4885SLC7A5 2995/4885PTGS1 1037/4885 |
| US-20140315785-A1 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS | VGF, NLN, BDNF | ADORA3 2358/4885SLC7A5 2995/4885PTGS1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.